Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Follicular Lymphoma Clinical Trials

A listing of Follicular Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (198) clinical trials

T-Lymphocytes in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

OBJECTIVES: Primary - To evaluate the safety of autologous T-lymphocytes genetically modified to express artificial T-cell receptors (CAR) targeting the CD19 molecule (CD19CAR) in patients with refractory or relapsed low-grade B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. Secondary - To measure the survival and function of CD19CAR T-cells in vivo. ...

Phase

Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma Multiple Myeloma or Chronic Lymphocytic Leukemia

OBJECTIVES: - Determine if allogeneic stem cell transplantation using unrelated matched or related haploidentical donor bone marrow or unrelated matched cord blood results in timely, complete, and durable engraftment in patients with previously treated lymphoma, multiple myeloma, or chronic lymphocytic leukemia. - Determine the incidence and grade of acute and ...

Phase

Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies

Myeloablative hematopoietic progenitor cell transplantation (HPCT) remains the standard of care for patients requiring HPCT. The purpose of this study is to evaluate the morbidity and mortality of myeloablative HPCT at Children's Memorial Hospital. It will also look to determine the toxicity of a single conditioning regimen consisting of total ...

Phase

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

OBJECTIVES: Primary - To determine the proportion of patients with CNS lymphoma who develop anti-idiotype (Id) and anti-keyhole limpet hemocyanin (KLH) humoral immune responses in the serum and/or CSF following patient-specific immunotherapy comprising recombinant tumor-derived immunoglobulin Id-KLH conjugate vaccine and sargramostim (GM-CSF). - To assess the safety and tolerability of ...

Phase

Fludarabine Busulfan and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease

OBJECTIVES: - To assess the safety and feasibility of reduced-intensity preparative regimen comprising fludarabine, busulfan, and alemtuzumab followed by allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies or other diseases. - To assess the rate of donor engraftment in patients treated with this regimen. OUTLINE: This is a ...

Phase

Rituximab Combination Chemotherapy and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma

OBJECTIVES: Primary - To evaluate the response rates in patients with relapsed follicular non-Hodgkin lymphoma treated with short-duration rituximab and combination chemotherapy (R-chemo) followed by rituximab and yttrium Y 90 ibritumomab tiuxetan. Secondary - To evaluate the duration of response in patients treated with this regimen. - To evaluate the ...

Phase

Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma

OBJECTIVES: Primary - To determine the overall survival in patients with untreated mantle cell lymphoma treated with fludarabine phosphate and cyclophosphamide with vs without rituximab. Secondary - To determine the progression-free survival in patients treated with this regimen. - To determine the toxicity of this regimen in these patients. - ...

Phase

T-cell Recovery in Patients With Leukemia Advanced Lymphoma Myelodysplastic Syndrome or Myeloproliferative Disorder Receiving Alemtuzumab and Undergoing Donor Stem Cell Transplant

OBJECTIVES: Primary - To define the biologic recovery and behavior of T-regulatory cells in patients undergoing stem cell transplantation. - To determine if the administration of alemtuzumab as part of conditioning therapy to patients undergoing stem cell transplantation from mismatched-related donors or from matched-unrelated donors permits T-regulatory cell recovery. OUTLINE: ...

Phase N/A

High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

OBJECTIVES: Primary - To assess the efficacy and toxicity of intensive high-dose chemotherapy (alternating I'VE regimen and intermediate-dose methotrexate) followed by autologous peripheral blood stem cell transplantation for treatment of patients with intestinal T-cell lymphoma. Secondary - To assess the toxicity of the regimen in a large population of these ...

Phase